Part of Dana-Farber Cancer Institute and affiliated with Harvard Medical School, the Belfer Institute is built upon a tradition of research excellence and a history of medical innovation. Our scientists are leaders in their fields and our organized and integrated research teams leverage a broad network of research centers of excellence. As a result, we are at the forefront of developing the next generation of cancer therapies. The Belfer Institute recently named two new scientific co-directors and a head of research, adding to its world-class team and continuing to grow its expertise.
In the News
Dr. P. Janne and Dr. C. Paweletz discuss an innovative approach for tumor genotyping and disease monitoring for targeted lung cancer therapies.
Belfer & Janssen announce collaboration on cancer immunotherapies for lung cancer
Phase I Study of Novel Third-Generation EGFR Inhibitor Holds Promise Against Resistance Mutation in Patients With Non–Small Cell Lung Cancer
Belfer scientists identified phospho-IRF3 as a biomarker of TBK1 activity in K-Ras mutant pancreatic cancer. TBK1 inhibition may have therapeutic potential in defined patient populations.
Poster presentation, PDx Platform of High Grade Serous Ovarian Cancer, at the 2014 AACR General Meeting in San Diego by Sangeetha Palakurthi PhD, Head of Cancer Biology and Pharmacology.